Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16299
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pham, Daniel | - |
dc.contributor.author | Kron, Tomas | - |
dc.contributor.author | Bressel, Mathias | - |
dc.contributor.author | Foroudi, Farshad | - |
dc.contributor.author | Hardcastle, Nicholas | - |
dc.contributor.author | Schneider, Michal | - |
dc.contributor.author | Soteriou, Sally | - |
dc.contributor.author | Innes, Jayson | - |
dc.contributor.author | Siva, Shankar | - |
dc.date | 2015-08-20 | - |
dc.date.accessioned | 2016-09-29T02:42:57Z | - |
dc.date.available | 2016-09-29T02:42:57Z | - |
dc.date.issued | 2015-11 | - |
dc.identifier.citation | Practical Radiation Oncology 2015; 5(6): e597-e605 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16299 | - |
dc.description.abstract | PURPOSE: Stereotactic ablative body radiation therapy for primary kidney cancer treatment relies on motion management that can quantify both the trajectory of kidney motion and stabilize the patient. A prospective ethics-approved clinical trial of stereotactic treatment to primary kidney targets was conducted at our institution. Our aim was to report on specific kidney tumor motion and the inter- and intrafraction motion as seen on treatment. METHODS AND MATERIALS: Patients with tumor size <5 cm received a dose of 26 Gy in 1 fraction and those with tumor size ≥5 cm received 42 Gy in 3 fractions. All patients underwent a 4-dimensional computed tomography planning scan, immobilized in a dual-vacuum system. A conventional linear accelerator cone beam computed tomography scan was used for pre-, mid-, and posttreatment imaging to verify target position. RESULTS: Between July 2012 and October 2014, 33 targets from 32 consecutive patients (24 males/8 females) were treated. Seventeen targets were prescribed 26 Gy/1 fraction and the remaining 16 targets received 42 Gy/3 fractions. Kidney motion at each of the poles was not affected by the presence of tumor (P = .875), nor was the motion statistically different from the corresponding contralateral kidney pole (P = .909). The mean 3-dimensional displacement of the target at mid- and posttreatment was 1.3 mm (standard deviation ± 1.6) and 1.0 mm (standard deviation ± 1.3), respectively. The maximum displacement in any direction for 95% of the fractions at mid- and posttreatment was ≤3 mm. CONCLUSION: In summary, stereotactic ablative body radiation therapy of primary kidney targets can be accurately delivered on a conventional linear accelerator with protocol that has minimal intrafractional target motion. | en_US |
dc.subject | Kidney Neoplasms | en_US |
dc.subject | Movement | en_US |
dc.subject | Radiosurgery | en_US |
dc.subject | Respiratory-Gated Imaging Techniques | en_US |
dc.title | Image guidance and stabilization for stereotactic ablative body radiation therapy (SABR) treatment of primary kidney cancer | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Practical Radiation Oncology | en_US |
dc.identifier.affiliation | Department of Radiation Therapy Services, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Medical Imaging and Radiation Sciences, Monash University, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Radiation Oncology | en_US |
dc.identifier.affiliation | Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Wellness and Research Centre | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/26547828 | en_US |
dc.identifier.doi | 10.1016/j.prro.2015.08.002 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Foroudi, Farshad | |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Radiation Oncology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.